Construct Capital

Constructive Bio is a synthetic biology company focused on rewriting genomes to create novel classes of enzymes, proteins, and biomaterials. Based on the research of Professor Jason Chin at the MRC Laboratory of Molecular Biology, the company utilizes a proprietary platform for large-scale genome synthesis and genetic code expansion. By incorporating non-canonical amino acids, Constructive Bio aims to develop new therapeutics and sustainable materials with properties not found in nature. The company's technology enables the creation of organisms with entirely synthetic genomes that are resistant to viruses and capable of producing complex non-natural polymers. This approach has the potential to revolutionize the production of biologics and create entirely new categories of medicine.